primary care
CREDENCE:
Type 2 Diabetes Management
- A New Perspective
Protect the kidney to protect the heart
Join us for our upcoming online webcast taking place on
22 July 2020 at 12.30 and 19.00
Taking place online
What does the CREDENCE trial mean for the management of diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) for primary care?
- The recent licence extension to Invokana
- How the licence change could change your management of DKD in T2DM
- Kidney function, its assessment and the interpretation of common tests.
This webcast has a very practical focus, and we believe it will be of great benefit to all primary care healthcare professionals wishing to know more about DKD in T2DM (see the agenda below for full details).
This 80-minute broadcast includes a 20-minute live Q&A, where you will be able to ask your questions to the speakers, and will be broadcast twice, at 12.30 and 19.00 on 22 July 2020.Your Speakers
Dr Kevin Fernando
GP, North Berwick, near Edinburgh
Dr Kevin Fernando is a part-time GP Partner and GP Educational Supervisor working at the coalface in North Berwick Health Centre, near Edinburgh. Dr Fernando is also Scottish Lead for the Primary Care Diabetes Society, and an observer member of the Primary Care Cardiovascular Society. His other roles include Royal College of General Practitioners Clinical Advisor for Diabetes and Multimorbidity, and Education Director for GPNotebook Education.
Dr Fernando graduated from the University of Edinburgh in 2000. He holds both MRCGP and MRCP(UK) qualifications, and has completed a Masters degree in diabetes which he passed with distinction.
Dr Fernando has been elected to the Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh and the Academy of Medical Educators for his work in diabetes and medical education.
Dr Amrit Lamba
GP and Partner at Colindale Medical Centre, London
Dr Amrit Lamba is a GP Partner at Colindale Medical Centre in Barnet Clinical Commissioning Group. He is also a lead clinician for the Barnet Federated GPs Diabetes Network and a board member for the Community Diabetes Service.
Dr Lamba is a clinical cluster lead for the Barnet Federated GPs Research Network, supporting local primary care participation in national research projects. In 2017, Dr Lamba founded the Barnet Diabetes Forum, which hosted regular educational events and networking opportunities for primary care clinicians with an interest in diabetes.
Professor David Wheeler
Honorary Consultant Nephrologist, Professor of Kidney Medicine, Royal Free, London
Professor David Wheeler’s current positions include Professor of Kidney Medicine at University College London, Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust and Honorary Professorial Fellow of the George Institute for Global Health, Sydney, Australia. He is a Clinician Scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has contributed to the development and running of several large-scale clinical trials involving patients with chronic kidney disease including SHARP, EVOLVE and CREDENCE. He is currently co-chief investigator of the DAPA-CKD study.
Locally, Professor Wheeler heads the clinical research team at the Centre for Nephrology, Royal Free Hospital in London. He has been involved in Clinical Practice Guideline Development for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently co-chair. He has served terms as President of the UK Renal Association, Chair of the UK Renal Registry and Associate Editor of Nephrology Dialysis Transplantation (NDT).
Agenda
22 July 2020
Session 1 (10 mins)
Chair's introduction
Current management of DKD in type 2 diabetes
Setting the scene
- Cardiovascular and renal outcome studies to date
- The importance of kidney protection
- The need: early renal protection in primary care
Dr Kevin Fernando
(chair)
Session 2 (20 mins)
Bringing CREDENCE to life: what does the data show?
- Study background and design
- What does this data add?
-
Practical implications of CREDENCE
- Cases illustrating how practice may change in light of the licence extension
- Dosing considerations
Prof David Wheeler
Session 3 (30 mins)
Management of DKD in type 2 diabetes –
past present and future: CREDENCE in context
-
How to assess kidney function
- eGFR and ACR
- Practical considerations for ordering tests
- Who do we test and how do we interpret the results?
- When is canagliflozin an appropriate option?
Dr Amrit Lamba
Session 4 (20 mins)
Live Q&A
Moderated by the Chair
Book your place on our upcoming webcast
What does the CREDENCE trial mean for the management of diabetic kidney disease in type 2 diabetes for primary care?
22 July 2020
12.30 and 19.00
Upcoming webcast
Napp Pharmaceuticals Limited
Specialist Care
Type 2 Diabetes Management -
A New Perspective
In association with
Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk
Date of preparation: July 2020 UK/INV-20106j
